Feature | January 21, 2014

IMV Market Report Shows U.S. CT Procedure Volume Dropping

January 21, 2014 — Computed Tomography (CT) procedure rates have declined by an average annual 5.5 percent in the United States over the past two years, diverging from a previous decade-long growth trend, according to a survey conducted by IMV Medical Information Division. 
 
“This apparent decline in CT procedures over the past couple years may in part be due to the reimbursement policies of Medicare and third-party insurers, who have tightened their reimbursements for key CT studies,” said Lorna Young, senior director of market research at IMV.
 
Pressures on CT departments that are impacting procedure rates include reduced reimbursements, necessary prior authorization for imaging studies, upholding department accreditations and national and regional policy reforms. IMV’s survey revealed about two-thirds of CT providers agree “the impact of federal healthcare reform is so uncertain that our facility has slowed the rate of all capital equipment spending until we know what the outcome is.” 
 
Reportedly, independent imaging centers with budgets to balance are more sensitive than hospitals to revenue-diminishing reductions in Medicare payments and third-party reimbursements. 
 
For more information: www.imvinfo.com

Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now